Abstract
Background COVID-19 has affected most countries and declared as pandemic. Most countries have implemented some social restrictions to control it. In this work we will use mathematical modelling to assess the current social restrictions in controlling the spread of the disease.
Methods We formulate a simple susceptible-infectious-recovery (SIR) model to describe the spread of the coronavirus under social restrictions. The transmission rate in this model is considered variable to catch social restrictions impact. We analyze this model, then fit the model to 160 days induced death data in Italy, Iran, USA, Germany, France, India, Spain and China. we estimate some factors that help in understanding not only the spread of the disease but also assess the current social restriction in controlling this disease.
Results We find a formula for the basic reproduction function (R(t)) and the maximum number of daily infected people. Then estimate the model’s parameters with 95% confidence intervals in these countries. We notice that the model has excellent fit to the disease death data in all considered countries except Iran. The percentage of disease death estimated by the model in Germany and France are 3.8% and 1.2% respectively, which are close to reported percentages values. Finally, we estimate the time, after first reported death, spent under social restrictions to reduce the basic reproduction function (R(t)) to one unit. The times to do that in Italy, USA, Germany, France, Spain and China are 40, 50, 34,58, 31, and 15 days respectively. However, the Indian social restrictions in the 160 days were not enough to reach R(t) = 1.
Conclusion The transmission rate is between 0.1035–1.6076 and recovery rate is between 0–0.2456. The disease death rates calculated for Germany and France are more realistic than others with average value 0.0023. Extending the same social restrictions for enough time could control the disease in Italy, USA, Germany, France, India, Spain and China. While, more social restrictions are needed to control the disease in India.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.